Leow Pay Chin is a Singaporean pharmacist and regulatory specialist at the Health Sciences Authority of Singapore. He received his Ph.D. in Pharmacy from the National University of Singapore in 2010 and has over 10 years of experience in regulatory affairs, research, and teaching. His responsibilities include reviewing new drug and generic drug applications, organizing committee meetings, and supporting regulatory compliance activities.
1. Leow Pay Chin
Name: Leow Pay Chin
Nationality: Singaporean
Email: leowpaychin@gmail.com
Mobile: +65 96755806
Academic Qualifications
2010 Ph.D., Department of Pharmacy, National University of Singapore, Singapore
2005 B.Sc. (Pharmacy) (Honours), National University of Singapore, Singapore
Professional Experience
2016 Registered Pharmacist with Singapore Pharmacy Board, since 2005
2012 Regulatory Specialist, Therapeutic Product Branch, Health Sciences Authority, Singapore
2010 Research Scientist, Cancer Science Institute of Singapore, National University of Singapore
2009 Project Mentor, Department of Pharmacy, National University of Singapore, Singapore
2007 Teaching Assistant, Department of Pharmacy, National University of Singapore, Singapore
2006 Research Assistant, Department of Pharmacy, National University of Singapore, Singapore
2005 Clinical Pharmacist, Singapore General Hospital, Singapore
Regulatory Specialist
Therapeutic Product Branch, Health Sciences Authority, Singapore
Review the clinical efficacy and safety dossier of New Drugs Applications (NDAs), Generic drugs
Applications (GDA), Major variation applications (MAVs), Minor Drug Applications (MIVs).
Screen clinical and safety dossier of NDAs and MAVs for acceptance.
Organize and prepare documents for Medicines Advisory Committee meetings and communications.
Develop and implement a framework to enhance reclassification of medicines.
Led initiative for environmental scanning, research and development in the area of pharmacogenomics.
Support regulatory compliance activities for post-approval efficacy & safety alerts and product recalls.
Author and review clinical evaluation reports, post-market surveillance documents, Dear Healthcare
Professional Letters and HSA Adverse Drug Reaction bulletins.
Provide input and support in the development of the Oscar IT system for post-approval safety alerts.
Prepare and coordinate publication of monthly approval information on new drugs and indications on the
HSA website.
Honours & Awards
2010 Galderma Award, National University of Singapore Medicinal Chemistry Symposium 2010
2008 Best poster award, PharmSci@Asia Symposium
2006 National University of Singapore Graduate Scholarship
2005 Dean’s List
Publications
Gupta S, Yan B, Leow PC, Chin SY, Soong R, Petersson F (2015) Primary mucinous adenocarcinoma of the
epididymis: report of a rare case with molecular genetic characterization including mutation analysis of the
TP53 gene. Appl. Immunohistochem 23(4):308-12
Goh GH, Venkateswaran K, Leow PC, Loh KS, Thamboo TP, Petersson F (2014) Carcinoma cuniculatum of
the esophagus and tongue: report of two cases, including TP53 mutational analysis. Head Neck Pathology
8(3):261-8.
2. Leow Pay Chin
Leow PC, Bahety P, Boon CP, Lee CY, Tan KL, Yang T, Ee PLR (2014) Functionalized curcumin analogs as
potent modulators of the Wnt/β-catenin signaling pathway. European Journal of Medicinal Chemistry
71:67-80.
Gan FF, Kaminska KK, Yang H, Liew CY, Leow PC, So CL, Tu LNL, Roy A, Yap CW, Kang TS, Chui WK, Chew EH
(2013) Identification of Michael acceptor-centric pharmacophores with substituents that yield strong
thioredoxin reductase inhibitory character correlated to antiproliferative activity. Antioxid. Redox Signal
19(11):1149-65.
Subramaniam MM, Chan JYS, Leow PC, Venkateswaran K, Nathan SS, Soong R, Lee VKM (2013)
Dedifferentiated liposarcoma with unusual kaposiform morphology and whorl formation masquerading As
Kaposi's sarcoma: diagnostically challenging case confirmed by cytogenetic and TP53 mutation analysis.
Journal of Clinical Oncology 31(7): 101-5.
Leow PC, Soo RA, Soong R, Ou SH (2012) Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a
promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. Journal
of Thoracic Oncology 7(11): 1625-30.
Leow PC, Ku CS, Soh RA, Soong R (2012) Technological advances in the detection of novel fusion genes. eLS
reviews.
Nayak TR, Leow PC, Ee PL, Arockiadoss T, Ramaprabhu S, Pastorin G (2010) Crucial Parameters responsible
for Carbon Nanotubes toxicity. Current Nanoscience 6(2): 141-154.
Leow PC, Ong ZY, Ee PL (2010) Natural compounds as antagonist of canonical Wnt/β-catenin signaling.
Current Chemical Biology 4(1): 49-63.
Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL (2009) Antitumor activity of natural compounds, curcumin and
PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Investigational New Drugs
28(6):766-782.
Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH (2008) Independent predictors for mortality in patients
with positive Stenotrophomanas maltophilia cultures. Ann Acad Med Singapore 37(10):826-30.
Chan EC, Yap SL, Lau AJ, Leow PC, Toh DF, Koh HL (2007) Ultra-performance liquid chromatography /time-
of-flight mass spectrometry based metabolomics of raw and steamed Panax notoginseng. Rapid Commun
Mass Spectrom 21(4):519-28.